JDQ443: A Quickly-Advancing Oral KRAS(G12C) Inhibitor from Novartis
JDQ443
oral KRASG12C inhibitor ph. III candidate for NSCLC from de novo SBDD in SWII pocket Cancer Discov. Novartis, Basel, CH
Reviewer:
Loading...
oral KRASG12C inhibitor ph. III candidate for NSCLC from de novo SBDD in SWII pocket Cancer Discov. Novartis, Basel, CH